Acomhal Research Inc., a cancer research start-up founded by Fralin Biomedical Research Institute at VTC scientists, recently secured $305,000 in funding from the Virginia Tech Carilion Seed Fund, the Virginia Innovation Partnership Corporation, and angel investors. With a wave of new grants and investments, a cancer stem cell research company founded by Fralin Biomedical Research Institute …

The Board expands from 24 to 30 Directors to bring more diverse expertise and insight from Virginia’s Life Science Ecosystem. Richmond, VA (December 30, 2021) – The Virginia Bio Membership has elected six new Directors to the Virginia Bio Board. Joining the Board are: Gerry Brunk, Managing Director of Lumina Ventures; Jessica Foley, CSO of …

New collaboration with Johnson & Johnson Innovation announced with the aim to accelerate life science sector growth in the New River and Roanoke Valleys by providing access to expert mentors, programming, and commercialization resources for startup companies The GO Virginia Coalition today approved a grant award to the Virginia Tech Corporate Research Center (VTCRC) to fund the expansion …

ASR Group – exclusive sales and distribution partner – reports strong customer demand for the unique, rare sugar, accelerating the timeline for a second production plant. Bonumose, Inc. announces the achievement of regulatory and food application milestones in the United States and Canada for the low-glycemic, rare sugar tagatose, as the company progresses on time …

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) announces five awardees chosen in its prestigious annual “Make Your Medical Device Pitch for Kids!” competition to share $150,000 in grant funding from the U.S. Food and Drug Administration (FDA) to support the advancement of pediatric medical devices. In an unprecedented decision, the competition judges determined that all …

Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Programs HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn, MD, PhD, as Chief Medical Officer, effective January 1, 2022. Dr. Horn will lead the company’s growing clinical operations, clinical development, regulatory affairs, medical affairs, biometrics …